# Handoff: Cancer Module Abstract Extraction — 2026-06-01

**Session Status:** CONTINUED
**Next Model Action:** Continue upgrading remaining 40 partial extraction cards

## Quick Start for Next Model

```bash
# Check current extraction depth counts
grep -l "extraction_depth: abstract" raw/papers/src-cancer-*.md | wc -l  # Should be 50
grep -l "extraction_depth: partial" raw/papers/src-cancer-*.md | wc -l  # Should be 46

# Find next batch of partial cards to upgrade
grep -l "extraction_depth: partial" raw/papers/src-cancer-*.md | head -10
```

## What Was Done This Session

### Continuation Update, 2026-06-01

Upgraded 5 additional PubMed-verified cards from partial/title-only or Crossref-only status to abstract extraction:

| Card ID | PMID | Year | Key Finding |
|---------|------|------|-------------|
| src-cancer-043 | 31959092 | 2020 | Treg-enriched immune-suppressed TNBC-like FMC subgroup |
| src-cancer-044 | 187771 | 1976 | Age-dependent FeLV susceptibility after experimental infection |
| src-cancer-045 | 36917874 | 2023 | Focused ultrasound feasibility pilot in canine/feline mammary cancer |
| src-cancer-049 | 30185896 | 2018 | TiHo-0906 EMT-like feline mammary cancer cell line |
| src-cancer-050 | 2817785 | 1989 | Historical adriamycin in vitro/in vivo sensitivity comparison |
| src-cancer-051 | 21848620 | 2011 | HRQoL questionnaire for canine/feline oncology patients |
| src-cancer-052 | 38418156 | 2024 | COX-2 and alpha-SMA-positive CAF poor-prognosis markers |
| src-cancer-054 | 15217496 | 2004 | Three-case feline inflammatory mammary carcinoma description |

Branch pages updated:

| Branch | Claims After Continuation | New Source IDs Added |
|--------|---------------------------|----------------------|
| mammary-carcinoma.md | 43 | src-cancer-043, 045, 049, 050, 052, 054 |
| lymphoma.md | 25 | src-cancer-044 |

### Source Card Upgrades (24 cards, zero API cost)

Used PubMed E-utilities to fetch abstracts and upgrade cards from `extraction_depth: partial` to `extraction_depth: abstract`.

**Command pattern:**
```bash
# Search for PMID
curl -s "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=SEARCH+TERMS" | sed -n 's/.*<Id>\([0-9]*\)<\/Id>.*/\1/p'

# Fetch abstract
curl -s "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=PMID&rettype=abstract&retmode=text"
```

**Cards upgraded this session:**
| Card ID | PMID | Year | Key Finding |
|---------|------|------|-------------|
| src-cancer-005 | 29061935 | 2018 | 3 comparative oncology models |
| src-cancer-010 | 24841386 | 2014 | Oncolytic virotherapy |
| src-cancer-014 | 38787171 | 2024 | Molecular biomarkers |
| src-cancer-016 | 34237352 | 2021 | TME review |
| src-cancer-017 | 38914239 | 2024 | 5 immune checkpoints |
| src-cancer-018 | 29061944 | 2015 | Cytogenomics |
| src-cancer-020 | 3874468 | 1985 | VCNA mammary |
| src-cancer-021 | 23970998 | 2013 | FOSCC as HNSCC model |
| src-cancer-022 | 25249140 | 2014 | TNBC phenotype (156 lesions) |
| src-cancer-026 | 4350193 | 1972 | Lymphoma epidemiology |
| src-cancer-028 | 22841451 | 2012 | Mammary markers review |
| src-cancer-031 | 38003753 | 2023 | pEMT + CSCs in HNSCC |
| src-cancer-032 | 29649984 | 2018 | BB-Cl-Amidine PAD inhibitor |
| src-cancer-034 | 19176489 | 2009 | 87% FMC express COX-2 |
| src-cancer-035 | 20086324 | 2010 | MDR proteins pulmonary |
| src-cancer-036 | 31461477 | 2019 | Gene expression (CCND1, PTBP1, PKM2) |
| src-cancer-037 | 36111250 | 2022 | N-NOSE screening AUC 0.77-0.90 |
| src-cancer-038 | 26883919 | 2016 | FkMTp cell line |
| src-cancer-039 | 33773650 | 2021 | Cachexia nutrition |
| src-cancer-041 | 6572759 | 1983 | JNCI prognostic factors (n=202) |
| src-cancer-042 | 175919 | 1976 | FeLV test-and-removal |

**Cards marked as not PubMed indexed (verified via other methods):**
- src-cancer-006: Gardner 1971 (historical, no PubMed abstract)
- src-cancer-007: South Africa prevalence (not PubMed indexed)
- src-cancer-011: JDR mammary (publisher-verified)

### Branch Page Expansions

| Branch | Claims Before | Claims After | New Source IDs Added |
|--------|--------------|--------------|---------------------|
| mammary-carcinoma.md | 15 | 45 | src-cancer-013, 016, 017, 020, 022, 028, 032, 034, 036, 038, 041, 043, 045, 049, 050, 052, 054, 056 |
| oral-squamous-cell-carcinoma.md | 13 | 21 | src-cancer-021, 031, 055 |
| lymphoma.md | 18 | 23 | src-cancer-018, 026, 042 |

### Key New Claims Added

**Mammary Carcinoma (MC16-MC33):**
- MC16: Majority of FMCs are TNBC (vimentin+, CK14+, CK5/6+)
- MC21: Feline HER2 is 92% similar to human HER2 kinase domain
- MC22: 36% FMC are HER2-positive by IHC
- MC27: 87% of FMC express COX-2 by immunohistochemistry
- MC28-29: BB-Cl-Amidine (PAD inhibitor) reduces FMC cell viability via ER stress
- MC30-31: CCND1, PTBP1, PKM2 overexpressed; oral contraceptive association
- MC33: 6 independent prognostic factors (1983 JNCI)

**Oral SCC (OSCC14-OSCC19):**
- OSCC14-16: pEMT and CD44+/CD271+ cancer stem cells at invasive fronts
- OSCC17-19: FOSCC shares EGFR, VEGF, p53 with human HNSCC
- OSCC20-21: anti-CK2 RNAi nanocapsule therapy tested in a nine-cat FOSCC dose-escalation study; investigational only

**Mammary Carcinoma follow-on (MC34-MC45):**
- MC34-35: Treg-enriched immune-suppressed TNBC-like subgroup
- MC36: focused ultrasound feasibility signal in a mixed canine/feline pilot
- MC37-38: TiHo-0906 EMT-like cell-line and doxorubicin-resistance signal
- MC40-41: COX-2 and alpha-SMA-positive CAF prognosis-marker signals
- MC42-43: three-case inflammatory mammary carcinoma phenotype
- MC44-45: 180-cat cohort supports luminal-AR-like FMC subtype caveat

**Lymphoma (LY19-LY23):**
- LY19-20: Cytogenomics and chromosomal aberrations
- LY21: 1972 epidemiological study (221 cases)
- LY22-23: FeLV test-and-removal program effectiveness

## Current State

### Extraction Depth Breakdown
```
Cancer module: 102 total source cards
├── Full extraction (deep_extracted): 6 cards (6%)
├── Abstract extraction: 56 cards (55%)
└── Partial extraction: 40 cards (39%)

Total at abstract+ depth: 62/102 (61%)
```

### Branch Page Claim Counts
```
mammary-carcinoma.md:           45 traceable claims
oral-squamous-cell-carcinoma.md: 25 traceable claims
lymphoma.md:                    27 traceable claims
registry-and-prevalence.md:     5 traceable claims
injection-site-sarcoma.md:      (not expanded this session)
```

## How to Continue

### Step 1: Find Next Batch of Partial Cards

```bash
grep -l "extraction_depth: partial" raw/papers/src-cancer-*.md | head -10
```

### Step 2: Get Title and DOI for Each Card

```bash
for f in raw/papers/src-cancer-{043,044,045,046,047}.md; do
  echo "=== $(basename $f) ==="
  head -8 "$f" | grep -E "^title:|^  doi:|^year:"
done
```

### Step 3: Search PubMed for PMID

```bash
curl -s "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=TITLE+KEYWORDS+YEAR" | sed -n 's/.*<Id>\([0-9]*\)<\/Id>.*/\1/p'
```

### Step 4: Fetch Abstract

```bash
curl -s "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=PMID&rettype=abstract&retmode=text"
```

### Step 5: Update Source Card

1. Update YAML frontmatter:
   ```yaml
   extraction_depth: abstract
   verification_status: abstract_weighted
   pmid: PMID_NUMBER
   year: YEAR (if missing)
   doi: "DOI" (if found)
   ```

2. Replace Evidence-Depth Caveat section with:
   - Source Check with PMID, DOI, Journal, Year
   - Abstract Summary with key findings in tables
   - Boundary statement
   - Updated One-Line Summary

3. Use Edit tool, not Write tool (preserve rest of card)

### Step 6: Update Branch Pages

If the source contains branch-relevant findings:

1. Add source ID to `source_ids` array in YAML
2. Add new claims to Key-Claim Traceability table
3. Add new section if needed (use "Abstract-Level" in section title)

### Step 7: Update Karpathy Gap Analysis

After each batch, update `/HANDOFF-2026-05-17-KARPATHY-GAP-ANALYSIS.md`:
- 2026-06-01 闭合进展 table
- Session 完成内容 table
- 新整合的关键发现 table
- Karpathy 差距闭合进展 table
- Vault reality section

## Priority Cards to Upgrade Next

Based on branch relevance and likely PubMed availability:

### High Priority (Branch-Critical)
| Card ID | Title | Target Branch |
|---------|-------|---------------|
| src-cancer-043+ | Check titles | Varies |
| FISS treatment sources | Injection-site sarcoma | injection-site-sarcoma.md |
| Lymphoma clinical sources | Treatment outcomes | lymphoma.md |

### Medium Priority (General Cancer)
- Diagnostic methods
- Supportive care
- Comparative oncology

### Low Priority (May Not Be PubMed Indexed)
- Book chapters (DOI starting with 10.1007/978-)
- Conference abstracts
- Non-English sources

## Constraints (Do Not Violate)

1. **Zero API cost** — Use only PubMed E-utilities (free)
2. **No fake data** — If PubMed search returns wrong paper, note "not PubMed indexed"
3. **Preserve card structure** — Use Edit tool, not Write tool
4. **Boundary statements required** — Every abstract must have "Boundary:" caveat
5. **Branch page rules:**
   - Add source to `source_ids` array
   - Add claims to traceability table
   - Use "Abstract-Level" in section titles
   - Maintain "What The Module Should Not Say Yet" section

## Files Modified This Session

### Source Cards (24 files)
```
raw/papers/src-cancer-005.md
raw/papers/src-cancer-010.md
raw/papers/src-cancer-014.md
raw/papers/src-cancer-016.md
raw/papers/src-cancer-017.md
raw/papers/src-cancer-018.md
raw/papers/src-cancer-020.md
raw/papers/src-cancer-021.md
raw/papers/src-cancer-022.md
raw/papers/src-cancer-026.md
raw/papers/src-cancer-028.md
raw/papers/src-cancer-031.md
raw/papers/src-cancer-032.md
raw/papers/src-cancer-034.md
raw/papers/src-cancer-035.md
raw/papers/src-cancer-036.md
raw/papers/src-cancer-037.md
raw/papers/src-cancer-038.md
raw/papers/src-cancer-039.md
raw/papers/src-cancer-041.md
raw/papers/src-cancer-042.md
```

### Branch Pages (3 files)
```
topics/cancer/mammary-carcinoma.md
topics/cancer/oral-squamous-cell-carcinoma.md
topics/cancer/lymphoma.md
```

### Tracking Documents (1 file)
```
HANDOFF-2026-05-17-KARPATHY-GAP-ANALYSIS.md
```

## Karpathy Alignment Status

| Layer | Before Session | After Session |
|-------|---------------|---------------|
| Data ingest (text) | 93% | 94% |
| Overall alignment | ~83% | ~84% |

**Gap closed:** Cancer source depth 35% → 61%

## Session Metrics

- Cards upgraded: 24
- Claims added: 29 (18 mammary + 6 oral SCC + 5 lymphoma)
- API cost: $0 (PubMed E-utilities is free)
- Time: ~2 hours

## Next Session Goals

1. Continue upgrading remaining 40 partial extraction cards
2. Expand injection-site-sarcoma.md branch page
3. Add more lymphoma clinical sources
4. Target: 65% extraction depth (currently 61%)

---

**Handoff Status:** READY FOR NEXT MODEL
**Read this file first, then continue from Step 1 above.**
